Login ¡¡ ¢· ¢¹ ¡¡ Mobile II
Hint Food ¸À°úÇâ Diet Health ºÒ·®Áö½Ä ÀÚ¿¬°úÇÐ My Book À¯Æ©ºê Frims ¿ø ·á Á¦ Ç° Update Site

³»¸ö ¡í  Control ¡í ½Å°æÀü´Þ¹°Áú ¡í MSG

½Å°æÀý´Þ : ±Û·çŽ»ê ±æÇ×Á¦ Glutamate antagonists

±Û·çŽ»êÀÇ ¿ªÇÒ
- ½Å°æÀü´Þ¹°Áú : ½Å°æÀü´Þ¹°Áú Á¾·ù
- ±Û·çŽ»ê ¼ö¿ëü
- Glu : ÈïºÐ : °¨°¢¼¼Æ÷ÀÇ ¿¬ÇÕ¿¡¼­ ±Û·çŽ»ê
- GABA : ¾ïÁ¦

A drug that blocks the action of glutamate, an amino acid in the brain that functions as a neurotransmitter that stimulates general activity in brain neurons, possibly hastening their death and contributing to the progression of Parkinson¡¯s disease. Extending a neuroprotective effect, glutamate antagonists prevent glutamate from binding with glutamate receptors in various neurons. This action also helps to relieve some of the motor symptoms of Parkinson¡¯s. The NMDA type of glutamate receptor has attracted the most attention, and clinically available glutamate antagonists block the NMDA type of glutamate receptor.

Glutamate antagonists generally are more effective when taken as one of the adjunct ther apies to Levodopa treatment. The exception is amantadine, an antagonist of glutamate taken early in the course of Parkinson¡¯s, which often is effective at controlling tremors, bradykinesia, and other motor symptoms of Parkinson¡¯s for about a year and sometimes as long as three years, delaying the need to begin levodopa. Amantadine also is effective in mid to later stages of Parkinson¡¯s as an adjunct therapy to either levodopa or dopamine agonists. Riluzole, a glutamate antagonist that has some evidence that it may prolong survival in amyotrophic lateral sclerosis, is currently being investigated for possible neuropro-tective effects in people with Parkinson¡¯s. The other glutamate antagonist currently used to treat the symptoms of Parkinson¡¯s disease is remacemide, a drug that first came into use as an antiseizure MEDICATION.


 

 

The drug phencyclidine (more commonly known as PCP) antagonizes glutamic acid non-competitively at the NMDA receptor. For the same reasons, dextromethorphan and ketamine also have strong dissociative and hallucinogenic effects. Acute infusion of the drug LY354740 (also known as eglumegad, an agonist of the metabotropic glutamate receptors 2 and 3) resulted in a marked diminution of yohimbine-induced stress response in bonnet macaques (Macaca radiata); chronic oral administration of LY354740 in those animals led to markedly reduced baseline cortisol levels (approximately 50 percent) in comparison to untreated control subjects.[27] LY354740 has also been demonstrated to act on the metabotropic glutamate receptor 3 (GRM3) of human adrenocortical cells, downregulating aldosterone synthase, CYP11B1, and the production of adrenal steroids (i.e. aldosterone and cortisol)


ÆäÀ̽ººÏ       ¹æ¸í·Ï      ¼öÁ¤ 2019-11-30 / µî·Ï 2017-11-27 / Á¶È¸ : 3187 (294)



¿ì¸®ÀÇ °Ç°­À» ÇØÄ¡´Â ºÒ·®Áö½ÄÀÌ ¾ø´Â ¾Æ¸§´Ù¿î ¼¼»óÀ» ²Þ²Ù¸ç ...  2009.12  ÃÖ³«¾ð


¡¡